← Eichor
Study identifier: NCT06059690 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells

Condition: Glioblastoma Multiforme · Glycolytic Index · Epidermal Growth Factor Receptor  ·  Sponsor: Jonsson Comprehensive Cancer Center

PhasePhase 1/Phase 2
Planned participants50
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this project is to validate a new combined MRI and PET imaging technique as a biomarker or measure of glycolysis in brain tumors. To accomplish this, the investigators propose obtaining image-guided measures of tissue pH and biopsied tissue in tumor areas selected for bulk resection surgery. Investigators will then correlate the imaging measurements with pH, RNA expression, protein expression, and bioenergetics measurements of key glycolytic enzymes.

This description comes directly from the study's public registry record.

Talk to the study team

Raksha Nagaraj  ·  310-794-8995  ·  RNagaraj@mednet.ucla.edu

Saima Chaabane  ·  310-794-8995  ·  schaabane@mednet.ucla.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of California at Los AngelesLos Angeles, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06059690